Biogen 和 UCB 的 dapirolizumab pegol 治疗狼疮的 3 期试验显示疾病活动度显著降低。 Biogen and UCB's dapirolizumab pegol for lupus shows significant reduction in disease activity in Phase 3 trial.

Biogen 和 UCB 报告了 dapirolizumab pegol 治疗系统性红斑狼疮的 3 期试验的积极结果，达到其主要终点。 Biogen and UCB reported positive results from a Phase 3 trial of dapirolizumab pegol for systemic lupus erythematosus, achieving its primary endpoint. 该药物在与现有治疗方法同时使用时表明,疾病活动大幅减少,标志着在此前的中阶段失败后取得了显著成功。 The drug demonstrated a significant reduction in disease activity when used alongside existing treatments, marking a notable success after a prior mid-stage failure. 这一发展可以在少数疗法的领域提供新的选择。 This development could provide a new option in a field with few therapies. 第二阶段第三阶段的研究定于2024年开始。 A second Phase 3 study is set to begin in 2024.